SecBot SecBot
144 ·Filed Nov 12, 2026

XNCR

Xencor Inc
NEUTRAL
Impact 2/10
Horizondays Processed4d 19h ago SEC0001959173-26-007947
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The filing is a routine insider intent-to-sell notice with no material impact. Monitor for any subsequent Form 4 filings to confirm execution, but no further action warranted.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$38.13
T+0 close · Nov 12, 2026 · via day close
Latest settled
−2.73%
T+1 · $37.09
Vs SPY
−2.36%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $38.13entry
  2. T+1 · 4d ago −2.73%α −2.36% · $37.09
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bart Jan Cornelissen, an officer of Xencor, filed a Form 144 notice to sell 10,100 shares of common stock with an approximate market value of $402,182. The shares were acquired through ESPP purchases and restricted stock vesting in 2024 and 2025. The sale is small relative to the company's $3.0B market cap and appears routine.

Key Facts

  • Reporting person: Bart Jan Cornelissen, an officer of Xencor
  • Shares to be sold: 10,100 shares of common stock
  • Approximate value: $402,182
  • Shares acquired via ESPP purchase (884 shares on 12/10/2024) and restricted stock vesting (9,216 shares on 04/09/2025)
  • Broker: Fidelity Brokerage Services LLC
  • Filing date: 2026-11-12; proposed sale date: 11/11/2026

Financial Impact

Sale of 10,100 shares valued at ~$402K, representing ~0.013% of Xencor's $3.0B market cap

dilution

Risk Factors

  • Insider sale could be perceived negatively if it signals lack of confidence, but the small size relative to market cap mitigates this risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-007947
Document: 0001959173-26-007947-index.html0001959173-26-007947
Document: 0001959173-26-007947.txt0001959173-26-007947

Track record

20 reports on XNCR

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +67.24% at T+60 after the May 5, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $35.40 Now $35.40 +0.00% settles Nov 18
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $39.23 Now $35.40 −9.77% settles Nov 17
  3. Nov 12, 20264d ago Insider Cluster Neutral 4/10 Entry $37.09 to $35.40 Now $35.40 −4.56% ▼ −4.56% −2.65% vs SPY
  4. Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $38.13 to $37.09 Now $35.40 −7.16% ▼ −2.73% −2.36% vs SPY
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $39.97 to $38.13 Now $35.40 −11.43% ▼ −4.60% −4.25% vs SPY
  6. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $35.75 to $38.59 Now $35.40 −0.98% ▲ +7.94% +5.58% vs SPY
  7. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $34.05 to $35.75 Now $35.40 +3.96% ▲ +4.99% +4.68% vs SPY
  8. Oct 30, 202617d ago SC 13G/A Bearish 4/10 Entry $29.82 to $29.66 Now $35.40 −18.71% ▲ +0.54% +0.06% vs SPY
  9. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $29.99 to $29.21 Now $35.40 +18.04% ▼ −2.60% −2.22% vs SPY
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $29.18 to $29.99 Now $35.40 +21.32% ▲ +2.78% +2.22% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026